Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07052045

One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy

Stroke, especially acute ischemic stroke (AIS) caused by a blocked blood vessel in the brain, is a leading cause of death and long-term disability. When the blockage is in a large blood vessel, a procedure called endovascular therapy (EVT)-where the clot is removed using a catheter-is highly effective. However, the sooner EVT is done, the better the outcome for the patient.

Research has shown that delays between arriving at the hospital and starting EVT (called door-to-groin time) significantly reduce the chances of recovery. For example, reducing this time by just 15 minutes can mean 20 more patients (out of 1,000 treated) going home instead of to a care facility. Even a 10-minute improvement can result in over 100 extra days of independent living for patients and save more than $10,000 in healthcare costs per patient.

To reduce these delays, hospitals have improved stroke workflows. In the current standard approach, patients suspected of having a stroke are taken first to a CT scan room to confirm the diagnosis, and then, if a treatable occlusion is found, to a separate room for EVT. This usually takes around 60-70 minutes.

However, moving patients between rooms takes time. A new approach called "One-Stop management" could solve this. In this method, both the brain scan and the EVT procedure are done in one room-the angiography suite-using special imaging tools called flat panel CT (FDCT) and FDCT angiography (FDCT-A).

A previous study with 230 patients showed that One-Stop management is possible and saves time. But there's a challenge: the decision to follow the One-Stop pathway is made before a clear diagnosis is available. That's important because not all strokes benefit from EVT. Severe stroke symptoms (measured by a score called NIHSS ≥10) can come from:

* A large or medium vessel blockage (which EVT can treat), * A small vessel blockage, or * A bleed in the brain (hemorrhage). Only the first group benefits from EVT. About 85% of patients with severe symptoms fall into this category. The rest-about 15%-would not benefit, and there are concerns that FDCT might be slightly less accurate than regular CT in diagnosing these types of strokes. So, we need to test whether One-Stop management is safe and effective for all patients, not just those with treatable blockages.

To do this, the GET-FAST trial will compare the One-Stop approach to the standard two-room process. Patients will be randomly assigned to one of the two strategies. Importantly, this randomization won't affect their actual treatment-everyone will still receive the best care according to current medical guidelines. The main endpoint for the evaluation of the One-Stop approach will be long-term (at 90 days) disability and dependency in daily life as measured with the modified Rankin Scale (mRS).

This study will include all patients as they were assigned, regardless of what type of stroke they actually had. This is called an "intention-to-treat" analysis, and it provides the most reliable measure of the overall impact of One-Stop management.

Another key aspect of the trial is that any CE-certified imaging system already used in hospitals can be used for the One-Stop process-no specific brand or model is required. This makes the results more applicable to real-world hospital settings.

If GET-FAST proves that One-Stop management leads to better patient outcomes, this could transform how stroke care is delivered. More patients could return to independent living, and fewer would require long-term care -leading to major reductions in healthcare costs. For example, even a one-point improvement on a common stroke disability scale (mRS) can triple the savings in lifetime care costs.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Klinik für Neurologie, Universitätsklinik der Paracelsus, Nuremberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Symptoms suggestive of an acute ischemic stroke caused by a large or medium vessel occlusion as defined by a National Institute of Health Stroke Scale (NIHSS) Score of ≥ 10 points
  • Patient presents directly to the treating hospital (mothership patient) within 4.5 hours of last seen well (LSW)
  • Age ≥ 18 years
  • Patient was independent in daily activities prior to the stroke (pre stroke modified Rankin Scale of 0 - 2)
  • Endovascular treatment team available (Neurologist, Interventionist, Anesthesiologist, Nursery, Technicians)
  • Informed Consent as documented by signature or fulfilling the criteria for emergency consent procedures

Exclusion criteria

  • Severe comorbidities, which will likely prevent improvement or follow-up
  • In-hospital stroke
  • Clinical symptoms suggestive of intracranial hemorrhage (deterioration of patient during transport, vomiting or depressed consciousness)
  • Strong suspicion of functional neurological symptom disorder / conversion disorder
  • Hemodynamically unstable patients who require advanced vital support
  • Angiography room occupied by other procedure

Treatment and study plan

One Stop Management

Other

Patients within the intervention group will be transported directly after randomization to the angiography room. In the angiography room diagnostic imaging will be performed using cranial non-contrast FDCT and FDCT-A with subsequent EVT (if a treatable vessel occlusion was identified). Therefore, diagnostics and treatment will be performed in the same room (One-Stop management). Only patients with a treatable occlusion will undergo arterial puncture.

Usual care management

Other

Patients within the control group will be transported directly after randomization to the multidetector CT (MDCT) room for diagnostic imaging with non-contrast MDCT and MDCT-A. IVT will be given directly in the MDCT room if no contraindication is present. If on diagnostic imaging a treatable vessel occlusion was identified, the patient will be transported to the angiography room, where EVT will be performed.

Primary outcomes

  1. Degree of Dependency and disability in daily activities

    Time frame: 90 days (+/- 15 days) after randomization

    As assessed with the modified Rankin Scale (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).

Secondary outcomes

  1. Early neurological improvement

    Time frame: 5 - 7 days after randomization or discharge if earlier

    Early neurological improvement is defined as a decrease of at least 4 points on the National Institute of Health Stoke Scale (NIHSS) compared to baseline; range of NIHSS 0 - 42 with higher values indicating more severe neurological deficit

  2. Early neurological deterioration

    Time frame: 5 - 7 days after randomization or discharge if earlier

    Early neurological deterioration is defined as an increase of at least 4 points on National Institutes of Health Stroke Scale compared to baseline, death or persistent coma; range of NIHSS 0 - 42 with higher values indicating more severe neurological deficit

  3. Independent functional outcome

    Time frame: 90 days (+ / - 15 days) after randomization

    Defined as a modified Rankin Scale of 0 to 2 (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).

  4. Cognitive function

    Time frame: 90 days (+/- 15 days) after randomization

    As assessed with the Montreal Cognitive Assessment Test (MoCA); range 0 - 30 with lower values indicating more severe cognitive impairment

  5. Health-related quality of life

    Time frame: 90 days (+/- 15 days) after randomization

    As assessed with the Euro-Qol 5d; 5 point scale with higher values indicating better quality of life in the specific domain

  6. Degree of Dependency and disability in daily activities

    Time frame: 365 days (+/- 30 days) after randomization

    As assessed with the modified Rankin Scale (mRS); The mRS runs from 0-6, running from perfect health without symptoms (0) to death (6).

  7. Health-related quality of life

    Time frame: 365 days (+/- 30 days) after randomization

    As assessed with the Euro-QoL-5D; 5 point scale with higher values indicating better quality of life in the specific domain

  8. Cognitive function

    Time frame: 365 days (+/- 30 days) after randomization

    As assessed with the telephone Montreal Cognitive Assessment Test (T-MoCA); range 0 - 22 with lower values indicating more severe cognitive impairment

Other outcomes

  1. Safety: Symptomatic intracranial hemorrhage

    Time frame: Within 24 hours (+/- 12 hours) after randomization

    All intracerebral hemorrhages will be classified by the blinded Core Lab according to the Heidelberg Bleeding Classification.

    Symptomatic intracerebral hemorrhage (sICH) will be defined using a modified SITS-MOST definition:

    sICH is defined as the presence of a parenchymal hemorrhage type 2 (local or remote), subarachnoid hemorrhage, and/or intraventricular hemorrhage on imaging performed 24 hours post-treatment (±12 hours), in combination with one of the following: A neurological deterioration of ≥4 points on the National Institute of Health Stroke Scale (NIHSS; ranging from 0 - 42 with higher values indication more severe neurological deficit) from baseline, or from the lowest NIHSS value between baseline and 24 hours; persistent coma; or Death.

  2. Safety: Serious Adverse Events

    Time frame: Within 90 days after randomization

  3. Safety: Mortality

    Time frame: Within 90 days after randomization

    All-cause mortality

Study contacts

Contact information is provided by the study sponsor or research team.

Alex Brehm, PhD

CONTACT

[email protected]

+41 61 328 79 48

Sponsors and collaborators

Lead sponsor

Prof. Dr. Jan Liman

Other

Collaborators

  • Deutsche Forschungegemeinschaft
  • Klinikum Nürnberg
  • University Hospital, Basel, Switzerland

Registry information

Official study title

One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy - An International, Multicenter, Pragmatic Randomized Controlled Trial (GET-FAST

Acronym: GET-FAST

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jul 4, 2025
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.